Can I read New developments in the prospects for GLP‐1 therapy on EtoBox?

New developments in the prospects for GLP‐1 therapy by Stefan Trapp; S. Clare Stanford is a Biochemistry, Genetics and Molecular Biology article available to read on EtoBox.

What is New developments in the prospects for GLP‐1 therapy about?

The glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide, has recently been confirmed as the most efficacious weight-loss drug in clinical use , which highlights a major success in the clinical exploitation of the humble 30 amino acid incretin hormone, GLP-1.An incretin is a hormone, produced by the digestive system, that promotes the lowering of the concentration of glucose in the plasma by stimulating the secretion of pancreatic hormones, particularly insulin. The incretin effect describes the more effective stimulation of insulin release following oral ingestion of glucose, by comparison with that induced by infusion of glucose directly into the bloodstream. Thus, after its identification as an incretin in the 1980s, early interest in GLP-1 focussed on this effect and led to the development of degradation-resistant GLP-1 receptor agonists, such as exenatide, liraglutide, albiglutide and others, which are now used successfully in the clinic as second-line treatments for type 2 diabetes mellitus. Since then, evidence gathered through clinical use of these agonists, as well as intense preclinical research, has increased our understanding of the physiology of GLP-1 apprecia

Who reads New developments in the prospects for GLP‐1 therapy?

Author

Stefan Trapp; S. Clare Stanford

Publisher

Wiley

Published

2022

Language

EN

Field

Biochemistry, Genetics and Molecular Biology (Life Sciences)